Summit Therapeutics is trading at $17.13, up 4.51% on September 30, 2026, following AstraZeneca’s $2 billion equity investment and collaboration on cancer-drug studies.
- The deal was announced September 28.
- Reuters reported Summit shares rose over 15% in extended trading after the announcement; AstraZeneca’s investment is priced at $18.36 per common share.
- Broader markets are also higher, which may add support, while the investment and collaboration remain the main company-specific catalyst.